CN101100657B - 大规模生产病毒抗原的方法 - Google Patents
大规模生产病毒抗原的方法 Download PDFInfo
- Publication number
- CN101100657B CN101100657B CN2007101271424A CN200710127142A CN101100657B CN 101100657 B CN101100657 B CN 101100657B CN 2007101271424 A CN2007101271424 A CN 2007101271424A CN 200710127142 A CN200710127142 A CN 200710127142A CN 101100657 B CN101100657 B CN 101100657B
- Authority
- CN
- China
- Prior art keywords
- cell
- virus
- culture
- biomass
- microcarrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract description 48
- 239000000427 antigen Substances 0.000 title abstract description 21
- 102000036639 antigens Human genes 0.000 title abstract description 21
- 108091007433 antigens Proteins 0.000 title abstract description 21
- 230000003612 virological effect Effects 0.000 title abstract description 20
- 238000011031 large-scale manufacturing process Methods 0.000 title abstract description 4
- 238000004113 cell culture Methods 0.000 claims abstract description 104
- 239000002028 Biomass Substances 0.000 claims abstract description 94
- 230000001464 adherent effect Effects 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 160
- 241000700605 Viruses Species 0.000 claims description 81
- 210000003501 vero cell Anatomy 0.000 claims description 27
- 241000712461 unidentified influenza virus Species 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 11
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims description 8
- 241000700618 Vaccinia virus Species 0.000 claims description 8
- 241000710942 Ross River virus Species 0.000 claims description 7
- 230000010261 cell growth Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 241000709721 Hepatovirus A Species 0.000 claims description 4
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 3
- 241000702263 Reovirus sp. Species 0.000 claims description 3
- 241000710886 West Nile virus Species 0.000 claims description 3
- 241000710772 Yellow fever virus Species 0.000 claims description 3
- 229940051021 yellow-fever virus Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 206010061494 Rhinovirus infection Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 22
- 238000004115 adherent culture Methods 0.000 abstract description 2
- 239000001963 growth medium Substances 0.000 abstract description 2
- 230000009385 viral infection Effects 0.000 description 18
- 230000001413 cellular effect Effects 0.000 description 17
- 230000012010 growth Effects 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003708 ampul Substances 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- -1 SEPIGEL 305 Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 208000007887 Alphavirus Infections Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000700646 Vaccinia virus WR Species 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/006881 | 2001-12-10 | ||
| US10/006,881 | 2001-12-10 | ||
| US10/006,881 US6951752B2 (en) | 2001-12-10 | 2001-12-10 | Method for large scale production of virus antigen |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028279778A Division CN100335619C (zh) | 2001-12-10 | 2002-12-10 | 大规模生产病毒抗原的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101100657A CN101100657A (zh) | 2008-01-09 |
| CN101100657B true CN101100657B (zh) | 2012-05-30 |
Family
ID=21723079
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101271424A Expired - Lifetime CN101100657B (zh) | 2001-12-10 | 2002-12-10 | 大规模生产病毒抗原的方法 |
| CNB028279778A Expired - Lifetime CN100335619C (zh) | 2001-12-10 | 2002-12-10 | 大规模生产病毒抗原的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028279778A Expired - Lifetime CN100335619C (zh) | 2001-12-10 | 2002-12-10 | 大规模生产病毒抗原的方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6951752B2 (enExample) |
| EP (3) | EP1894998A1 (enExample) |
| JP (2) | JP4370511B2 (enExample) |
| CN (2) | CN101100657B (enExample) |
| AT (1) | ATE447010T2 (enExample) |
| AU (1) | AU2002358662B2 (enExample) |
| CA (1) | CA2469644C (enExample) |
| DE (2) | DE122010000025I1 (enExample) |
| DK (2) | DK2330189T3 (enExample) |
| ES (2) | ES2488818T3 (enExample) |
| FR (1) | FR10C0026I1 (enExample) |
| HU (1) | HU225791B1 (enExample) |
| MX (1) | MXPA04005644A (enExample) |
| NO (1) | NO20042910L (enExample) |
| PL (1) | PL208232B1 (enExample) |
| RU (1) | RU2314344C2 (enExample) |
| WO (1) | WO2003054174A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| US6951752B2 (en) * | 2001-12-10 | 2005-10-04 | Bexter Healthcare S.A. | Method for large scale production of virus antigen |
| ATE302268T1 (de) * | 2001-12-20 | 2005-09-15 | Bavarian Nordic As | Methode zur gewinnung und reinigung von poxviren aus infizierten zellen |
| ES2305514T5 (es) | 2002-09-05 | 2019-06-14 | Bavarian Nordic As | Método para la amplificación de un poxvirus en condiciones exentas de suero |
| TWI312368B (en) * | 2002-12-23 | 2009-07-21 | Bristol Myers Squibb Compan | Mammalian cell culture processes for protein production |
| CA2551026A1 (en) * | 2003-12-23 | 2005-07-14 | Schering Corporation | Methods for producing a549 cell lines stable in serum-free medium suspension culture |
| JP2007522814A (ja) | 2004-02-23 | 2007-08-16 | クルセル ホランド ベー ヴェー | ウイルスの精製方法 |
| WO2005103235A1 (ja) * | 2004-04-19 | 2005-11-03 | Denka Seiken Co., Ltd. | ウイルスの生産方法 |
| NZ551640A (en) * | 2004-05-20 | 2010-05-28 | Id Biomedical Corp | Process for the production of an influenza vaccine |
| EP1831353B1 (en) * | 2004-12-23 | 2012-02-29 | MedImmune, LLC | Non-tumorigenic mdck cell line for propagating viruses |
| US7344839B2 (en) * | 2004-12-23 | 2008-03-18 | Aurx, Inc. | Virus preparations and methods |
| AU2007245192B2 (en) | 2006-03-31 | 2012-04-12 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| KR101464783B1 (ko) | 2006-09-15 | 2014-11-26 | 메디뮨 엘엘씨 | 높은 역가로 바이러스 증식을 지원하는 ｍｄｃｋ 세포주 및 이를 이용한 생물반응기 공정 |
| JP5084214B2 (ja) * | 2006-09-29 | 2012-11-28 | 一般財団法人日本ポリオ研究所 | Ｉｐｖワクチン |
| RU2476594C2 (ru) * | 2007-05-04 | 2013-02-27 | Бакстер Интернэшнл Инк. | Двухстадийный температурный профиль для культивирования вирусов |
| US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
| JP2011512877A (ja) * | 2008-03-12 | 2011-04-28 | ワイス・エルエルシー | 組換えタンパク質の大スケール産生に適した細胞を同定する方法 |
| CA2733356C (en) * | 2008-08-01 | 2016-06-07 | Gamma Vaccines Pty Limited | Influenza vaccines |
| CA2738024A1 (en) | 2008-09-24 | 2010-04-01 | Medimmune, Llc | Methods for purification of viruses |
| CN103952376A (zh) * | 2008-09-24 | 2014-07-30 | 米迪缪尼有限公司 | 培养细胞、增殖和纯化病毒的方法 |
| ES2524975T3 (es) | 2009-07-31 | 2014-12-16 | Ge Healthcare Bio-Sciences Corp. | Cepa del virus de la fiebre amarilla de alto rendimiento con mayor propagación en células |
| JP2013507990A (ja) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス |
| WO2011077035A1 (fr) * | 2009-12-23 | 2011-06-30 | Sanofi Pasteur | Procede de culture de cellules adherentes |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| WO2011130119A2 (en) | 2010-04-14 | 2011-10-20 | Millipore Corporation | Methods of producing high titer, high purity virus stocks and methods of use thereof |
| EP2625264B1 (en) | 2010-10-08 | 2022-12-07 | Terumo BCT, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| CN101979517B (zh) * | 2010-10-15 | 2011-12-28 | 普莱柯生物工程股份有限公司 | 一种利用生物反应器大规模生产流感病毒的方法 |
| EP2667891B1 (en) | 2011-01-27 | 2021-10-06 | Gamma Vaccines Pty Limited | Combination vaccines |
| JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
| CN102492659A (zh) * | 2011-11-14 | 2012-06-13 | 成都康华生物制品有限公司 | 一种疫苗生产用甲肝病毒的生产方法 |
| EP3022296B1 (en) | 2013-07-15 | 2022-12-28 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
| CN103387958B (zh) * | 2013-08-16 | 2016-04-06 | 北京科兴中维生物技术有限公司 | 人胚肺成纤维细胞sv-7在病毒培养中的应用 |
| EP3068866B1 (en) | 2013-11-16 | 2018-04-25 | Terumo BCT, Inc. | Expanding cells in a bioreactor |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| US20160090569A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled Feed |
| KR101983486B1 (ko) | 2015-01-26 | 2019-05-28 | 우베 고산 가부시키가이샤 | 폴리이미드 다공질막을 이용하는 세포의 대량 배양 방법, 장치 및 키트 |
| US10519478B2 (en) | 2015-01-26 | 2019-12-31 | Ube Industries, Ltd. | Method of producing substance |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| JP2019510481A (ja) | 2016-02-19 | 2019-04-18 | ウィスコンシン アルムニ リサーチ ファンデイション | ワクチン開発のための改善されたｂ型インフルエンザウイルス複製 |
| WO2017205667A1 (en) | 2016-05-25 | 2017-11-30 | Terumo Bct, Inc. | Cell expansion |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11932841B2 (en) | 2016-07-25 | 2024-03-19 | Ube Corporation | Cell cultivation module |
| JP6897680B2 (ja) | 2016-07-25 | 2021-07-07 | 宇部興産株式会社 | サイフォン式培養法 |
| CN110612344B (zh) | 2017-03-31 | 2023-09-12 | 泰尔茂比司特公司 | 细胞扩增 |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| EP3700562A1 (en) | 2017-10-25 | 2020-09-02 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized ha for replication in eggs |
| CN111615399A (zh) * | 2018-01-18 | 2020-09-01 | 依生生物制药(新加坡)私人有限公司 | 一种使流感病毒适应Vero细胞的方法 |
| SG11202007503WA (en) * | 2018-02-07 | 2020-09-29 | Bharat Biotech Int Ltd | A process for enterovirus purification and inactivation and vaccine compositions obtained thereof |
| JP7783047B2 (ja) | 2018-08-07 | 2025-12-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| EP3840780A1 (en) | 2018-08-20 | 2021-06-30 | Wisconsin Alumni Research Foundation | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein |
| EP3914295A2 (en) | 2019-01-23 | 2021-12-01 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
| KR102228267B1 (ko) * | 2019-01-25 | 2021-03-17 | 바이로큐어 주식회사 | Bhk-21 세포를 이용한 바이러스 생산방법 |
| WO2020153619A1 (ko) * | 2019-01-25 | 2020-07-30 | 바이로큐어 주식회사 | Bhk-21 세포를 이용한 바이러스 생산방법 |
| US11851648B2 (en) | 2019-02-08 | 2023-12-26 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| AU2020221305A1 (en) * | 2019-02-15 | 2021-08-26 | Ology Bioservices, Inc. | Method for virus production |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| TW202122569A (zh) | 2019-08-09 | 2021-06-16 | 日商宇部興產股份有限公司 | 應用小片多孔膜的細胞培養法 |
| TW202122572A (zh) | 2019-08-09 | 2021-06-16 | 日商宇部興產股份有限公司 | 胞外體的產生方法 |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CN111850169B (zh) * | 2020-07-16 | 2022-09-27 | 华农（肇庆）生物产业技术研究院有限公司 | 一种计算AIV在MDCK-sus细胞中细胞单位均产毒量的方法 |
| WO2022204315A1 (en) | 2021-03-23 | 2022-09-29 | Terumo Bct, Inc. | Cell capture and expansion |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719051A (en) * | 1989-12-22 | 1998-02-17 | Immuno Aktiengesellschaft | Perfusion system and a method for the large scale production of virus or virus antigen |
| US5994134A (en) * | 1998-05-04 | 1999-11-30 | Canji, Inc. | Viral production process |
| CN100335619C (zh) * | 2001-12-10 | 2007-09-05 | 巴克斯特健康护理股份有限公司 | 大规模生产病毒抗原的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4525349A (en) | 1981-12-29 | 1985-06-25 | Societe Anonyme Dite: Institut Merueux | Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine |
| AT393356B (de) | 1989-12-22 | 1991-10-10 | Immuno Ag | Verfahren zur herstellung von fsme-virus-antigen |
| FR2723740B1 (fr) | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
| US5824536A (en) * | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
| DK0791055T3 (da) | 1994-11-10 | 2012-04-16 | Baxter Healthcare Sa | Fremgangsmåde til fremstilling af biologiske produkter i proteinfri kultur |
| DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| GB2319413B (en) * | 1996-11-12 | 2001-06-06 | Lsi Logic Corp | Driver circuits |
| US6168944B1 (en) * | 1997-01-31 | 2001-01-02 | Schering Corporation | Methods for cultivating cells and propagating viruses |
| DE69835813T2 (de) * | 1997-01-31 | 2007-09-13 | Schering Corp. | Verfahren zur kultivierung von zellen und zur vermehrung von viren |
| AT407255B (de) | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| US6855535B2 (en) * | 2001-12-10 | 2005-02-15 | Baxter Healthcare S.A. | Method of large scale production of Hepatitis A virus |
-
2001
- 2001-12-10 US US10/006,881 patent/US6951752B2/en not_active Expired - Lifetime
-
2002
- 2002-12-10 EP EP07021348A patent/EP1894998A1/en not_active Withdrawn
- 2002-12-10 DK DK10011842.1T patent/DK2330189T3/da active
- 2002-12-10 EP EP10011842.1A patent/EP2330189B1/en not_active Expired - Lifetime
- 2002-12-10 MX MXPA04005644A patent/MXPA04005644A/es active IP Right Grant
- 2002-12-10 WO PCT/EP2002/014011 patent/WO2003054174A1/en not_active Ceased
- 2002-12-10 EP EP02792957.9A patent/EP1453956B2/en not_active Expired - Lifetime
- 2002-12-10 CN CN2007101271424A patent/CN101100657B/zh not_active Expired - Lifetime
- 2002-12-10 RU RU2004121178/13A patent/RU2314344C2/ru not_active IP Right Cessation
- 2002-12-10 DE DE122010000025C patent/DE122010000025I1/de active Pending
- 2002-12-10 DE DE60234211T patent/DE60234211D1/de not_active Expired - Lifetime
- 2002-12-10 AT AT02792957T patent/ATE447010T2/de active
- 2002-12-10 CA CA2469644A patent/CA2469644C/en not_active Expired - Lifetime
- 2002-12-10 PL PL373487A patent/PL208232B1/pl unknown
- 2002-12-10 CN CNB028279778A patent/CN100335619C/zh not_active Expired - Lifetime
- 2002-12-10 ES ES10011842.1T patent/ES2488818T3/es not_active Expired - Lifetime
- 2002-12-10 ES ES02792957.9T patent/ES2335395T5/es not_active Expired - Lifetime
- 2002-12-10 JP JP2003554878A patent/JP4370511B2/ja not_active Expired - Lifetime
- 2002-12-10 DK DK02792957T patent/DK1453956T3/da active
- 2002-12-10 HU HU0402415A patent/HU225791B1/hu not_active IP Right Cessation
- 2002-12-10 AU AU2002358662A patent/AU2002358662B2/en not_active Expired
-
2004
- 2004-07-09 NO NO20042910A patent/NO20042910L/no not_active Application Discontinuation
-
2005
- 2005-03-17 US US11/084,485 patent/US7524676B2/en not_active Expired - Lifetime
-
2009
- 2009-07-02 JP JP2009157882A patent/JP5021000B2/ja not_active Expired - Lifetime
-
2010
- 2010-04-16 FR FR10C0026C patent/FR10C0026I1/fr active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719051A (en) * | 1989-12-22 | 1998-02-17 | Immuno Aktiengesellschaft | Perfusion system and a method for the large scale production of virus or virus antigen |
| US5994134A (en) * | 1998-05-04 | 1999-11-30 | Canji, Inc. | Viral production process |
| CN100335619C (zh) * | 2001-12-10 | 2007-09-05 | 巴克斯特健康护理股份有限公司 | 大规模生产病毒抗原的方法 |
Non-Patent Citations (4)
| Title |
|---|
| KISTNER O ET AL.NOVEL MAMMALIAN CELL (VERO)DERIVEDINFLUEZYVIRUS VACCINE:DEVELOPMENT,CHARACTERIZATIONAND INDUSTRIALSCALEPRODUCTION.WIENER KLINISCHE WOCHENSCHRIFT111 5.1999,111(5),207-214,具体参见对比文件1摘要、第208页右栏第三段、及最后一段至第209页左栏第一段. * |
| KISTNEROETAL.NOVELMAMMALIANCELL(VERO)DERIVEDINFLUEZYVIRUSVACCINE:DEVELOPMENT CHARACTERIZATIONAND INDUSTRIALSCALEPRODUCTION.WIENER KLINISCHE WOCHENSCHRIFT111 5.1999 |
| SHARKEY C MATTHEW ET AL.Ross River virus glycoprotein-pseudotyped retroviruses andstable cell lines for their production..JOURNAL OF VIROLOGY75 6.2001,75(6),2653-2659. |
| SHARKEY C MATTHEW ET AL.Ross River virus glycoprotein-pseudotyped retroviruses andstable cell lines for their production..JOURNAL OF VIROLOGY75 6.2001,75(6),2653-2659. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101100657B (zh) | 大规模生产病毒抗原的方法 | |
| CN101058800B (zh) | 用于细胞培养的无动物蛋白质培养基 | |
| US20050118140A1 (en) | Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture | |
| CA2456561A1 (en) | Multiplication of viruses in a cell culture | |
| HK1115609B (en) | Method for large scale production of virus antigen | |
| Mazurkova et al. | Comparative analysis of reproduction of influenza virus strains in cell lines perspective for the creation of cultural vaccines grown on nutrient medium on the basis of rise flour protein hydrolysate | |
| HK1158691B (en) | Method for large scale production of virus | |
| HK1116825A (en) | Method for large scale production of virus | |
| HK1083635B (en) | Animal protein free media for cultivation of cells | |
| HK1108713B (en) | Animal protein free media for cultivation of cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1115609 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1115609 Country of ref document: HK |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160921 Address after: Swiss Aupu Patentee after: Baxter Co. Address before: Swiss Aupu Patentee before: Baxter Healthcare S.A. Effective date of registration: 20160921 Address after: American Florida Patentee after: nanomedicine Address before: Swiss Aupu Patentee before: Baxter Co. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20120530 |
|
| CX01 | Expiry of patent term |